
## Maja Relja

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11952722/publications.pdf Version: 2024-02-01



MAIA RELL

#	Article	IF	CITATIONS
1	Consensus guidelines for botulinum toxin therapy: general algorithms and dosing tables for dystonia and spasticity. Journal of Neural Transmission, 2021, 128, 321-335.	2.8	37
2	Lack of Accredited Clinical Training in Movement Disorders in Europe, Egypt, and Tunisia. Journal of Parkinson's Disease, 2020, 10, 1833-1843.	2.8	3
3	Update on the Management of Parkinson's Disease for General Neurologists. Parkinson's Disease, 2020, 2020, 1-13.	1.1	33
4	Defining spasticity: a new approach considering current movement disorders terminology and botulinum toxin therapy. Journal of Neurology, 2018, 265, 856-862.	3.6	51
5	Effect of botulinum toxin type-A treatment on non-motor symptoms and cognitive functions in patients with isolated adult-onset cervical dystonia. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO4-1-61.	0.0	0
6	Brainstem nuclei changes in migraine detected by transcranial sonography. Neurological Sciences, 2017, 38, 1509-1512.	1.9	5
7	When movement disorders hurt: Addressing pain in hyperkinetic disorders. Parkinsonism and Related Disorders, 2017, 44, 110-113.	2.2	12
8	Botulinum toxin therapy for treatment of spasticity in multiple sclerosis: review and recommendations of the IAB-Interdisciplinary Working Group for Movement Disorders task force. Journal of Neurology, 2017, 264, 112-120.	3.6	32
9	Clinical Practice: Evidence-Based Recommendations for the Treatment of Cervical Dystonia with Botulinum Toxin. Frontiers in Neurology, 2017, 8, 35.	2.4	63
10	Strategies for treatment of dystonia. Journal of Neural Transmission, 2016, 123, 251-258.	2.8	31
11	Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement. Journal of Neurology, 2015, 262, 2201-2213.	3.6	59
12	Clinical rating scales. Parkinsonism and Related Disorders, 2012, 18, S229-S232.	2.2	6
13	A dopamine agonist, pramipexole, and cognitive functions in Parkinson's disease. Journal of the Neurological Sciences, 2006, 248, 251-254.	0.6	21
14	Botulinum toxin in tension-type headache. Journal of Neurology, 2004, 251, 1-1.	3.6	20
15	Catabolism of Endogenous Dopamine in Peripheral Tissues: Is There an Independent Role for Dopamine in Peripheral Neurotransmission?. Iournal of Neurochemistry, 1982, 38, 1453-1458.	3.9	40